Review



lenalidomide 4'-peg3-amine  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Bio-Techne corporation lenalidomide 4'-peg3-amine
    Lenalidomide 4' Peg3 Amine, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lenalidomide 4'-peg3-amine/product/Bio-Techne corporation
    Average 99 stars, based on 26 article reviews
    lenalidomide 4'-peg3-amine - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    94
    MedChemExpress ikaros inhibitor lenalidomide
    A , B SerpinB2 was quantified in THP-1 macrophages after stimulation with IFN-γ in the presence or absence of Bay-118072, an NF-kB inhibitor, by qPCR ( A ) (n = 8/group) and confocal imaging ( B ) (n = 10/group). A , B each dot represents cells cultured in one well. C VAT from lean and obese mice were stained for the markers of fibroblasts, macrophages, and adipocytes along with IFN-γ. The frequencies of IFN-γ-expressing cells were assessed by confocal microscopy (n = 5/group) Scale bar=20 µm. D – J LysM +/+ Ifngr1 fl/fl and LysM cre/+ Ifngr1 fl/fl mice were fed with an HFD for four months. D VAT resident macrophages, SerpinB2-expressing macrophages, and caspase 3 + resident macrophages were measured by confocal microscopy (n = 12/group). E The frequencies of apoptotic (annexin V + PI − ) macrophages were measured by flow cytometry (n = 5 for WT and 4 for KO). F GTT and ITT were performed, and fasting blood glucose, serum insulin, lipid concentrations, and body weights were evaluated (n = 10/group, combined data of at least 2 independent experiments). G , H Immunoblot showing pAkt, total Akt, Glut4, adiponectin, and Ppar y expressions in muscle, visceral adipose. and liver (n = 6/group). I , J qPCR was carried out to measure the expression of the metabolic and inflammatory genes in VAT (n = 7/group). K , L The top four transcription factors predicted to bind to the SerpinB2 promoter ( K ), and ChIP validation of <t>Ikaros</t> binding to the SerpinB2 promoter ( L ) (n = 4/group, with two sets of primers) are shown. M Ikaros quantification by qPCR in BMDM cultured in the presence or absence of 250 milli units IFN-γ (n = 10 and 8 for with and without IFN-γ, respectively). L , M each dot represents cells cultured in one well. N SerpinB2 expression in BMDM treated with or without IFN-γ and <t>lenalidomide</t> (representative image of the 3 independent experiments). O Ifngr1 and Ifngr2 were quantified by RNA seq in the adipose macrophage subsets (n = 3/group, each dot represents one mouse.). P – R Evaluation of apoptosis in BMDM lacking SerpinB2 (P) (n = 6/group), THP-1 macrophages overexpressing SerpinB2 ( Q ) (n = 4/group), and VAT resident macrophages in obese SerpinB2 +/+ and SerpinB2 − / − mice ( R ) (n = 4 for WT and 6 for KO) by flow cytometry. * P < 0.05, ** P < 0.01, *** P < 0.001. The Mann Whitney test (two-tailed) was used to determine the significance between two groups. One-way ANOVA with Bonferoni’s post hoc correction test was performed to determine differences among data obtained from more than two groups (Fig. 4B).
    Ikaros Inhibitor Lenalidomide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ikaros inhibitor lenalidomide/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    ikaros inhibitor lenalidomide - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    99
    Bio-Techne corporation lenalidomide 4'-peg3-amine
    A , B SerpinB2 was quantified in THP-1 macrophages after stimulation with IFN-γ in the presence or absence of Bay-118072, an NF-kB inhibitor, by qPCR ( A ) (n = 8/group) and confocal imaging ( B ) (n = 10/group). A , B each dot represents cells cultured in one well. C VAT from lean and obese mice were stained for the markers of fibroblasts, macrophages, and adipocytes along with IFN-γ. The frequencies of IFN-γ-expressing cells were assessed by confocal microscopy (n = 5/group) Scale bar=20 µm. D – J LysM +/+ Ifngr1 fl/fl and LysM cre/+ Ifngr1 fl/fl mice were fed with an HFD for four months. D VAT resident macrophages, SerpinB2-expressing macrophages, and caspase 3 + resident macrophages were measured by confocal microscopy (n = 12/group). E The frequencies of apoptotic (annexin V + PI − ) macrophages were measured by flow cytometry (n = 5 for WT and 4 for KO). F GTT and ITT were performed, and fasting blood glucose, serum insulin, lipid concentrations, and body weights were evaluated (n = 10/group, combined data of at least 2 independent experiments). G , H Immunoblot showing pAkt, total Akt, Glut4, adiponectin, and Ppar y expressions in muscle, visceral adipose. and liver (n = 6/group). I , J qPCR was carried out to measure the expression of the metabolic and inflammatory genes in VAT (n = 7/group). K , L The top four transcription factors predicted to bind to the SerpinB2 promoter ( K ), and ChIP validation of <t>Ikaros</t> binding to the SerpinB2 promoter ( L ) (n = 4/group, with two sets of primers) are shown. M Ikaros quantification by qPCR in BMDM cultured in the presence or absence of 250 milli units IFN-γ (n = 10 and 8 for with and without IFN-γ, respectively). L , M each dot represents cells cultured in one well. N SerpinB2 expression in BMDM treated with or without IFN-γ and <t>lenalidomide</t> (representative image of the 3 independent experiments). O Ifngr1 and Ifngr2 were quantified by RNA seq in the adipose macrophage subsets (n = 3/group, each dot represents one mouse.). P – R Evaluation of apoptosis in BMDM lacking SerpinB2 (P) (n = 6/group), THP-1 macrophages overexpressing SerpinB2 ( Q ) (n = 4/group), and VAT resident macrophages in obese SerpinB2 +/+ and SerpinB2 − / − mice ( R ) (n = 4 for WT and 6 for KO) by flow cytometry. * P < 0.05, ** P < 0.01, *** P < 0.001. The Mann Whitney test (two-tailed) was used to determine the significance between two groups. One-way ANOVA with Bonferoni’s post hoc correction test was performed to determine differences among data obtained from more than two groups (Fig. 4B).
    Lenalidomide 4' Peg3 Amine, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lenalidomide 4'-peg3-amine/product/Bio-Techne corporation
    Average 99 stars, based on 1 article reviews
    lenalidomide 4'-peg3-amine - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    95
    MedChemExpress lenalidomide
    Summary of pomalidomide- and <t>lenalidomide-derivative</t> compound screen for HbF inducers in HUDEP-2 cells and unbiased global proteomic follow-up. For screening, cells were treated at stages 1 and 2 and collected at stage 3 (see ). ( A ) Pomalidomide (Poma) treatment (1 µM, 6 days) in HUDEP-2 cells induces a 4-fold increase of %HbF + cells as quantified by flow cytometry (p < 0.0001, two-sided t-test). ( B ) A total of 19 compounds induced HbF levels to at least 50% of the internal pomalidomide positive control, as quantified by flow cytometry. Compounds discussed in text are highlighted in color. Compounds 1088 (4-carbon linker), 1089 (5-carbon linker) and 1091 (7-carbon linker) share chemical structure similarity with 1090 , which contains a 6-carbon linker (Supplementary Table S4). ( C ) Direct targets of pomalidomide in HUDEP-2 cells (indicated by asterisks) include known targets IKZF1 and FAM83F and novel targets FBXO22, RASSF5, CDIP1, and KCTD15 (Supplementary Table S6). ( D ) Compound 1075 led to specific degradation of IKZF1 and ZFP91. ( E ) Compound 1090 led to degradation of a subset of major pomalidomide targets, with increased specificity for ZFP91 and CYP2R1. ( F ) Compound 1126 led to degradation of a subset of pomalidomide targets with increased specificity for CYP2R1 and ZPF91 and decreased specificity for IKZF1. ( G ) Compound 1235 , a derivative of lenalidomide, led to degradation of the known lenalidomide targets (indicated by asterisks) IKZF1, CSNK1A1, and FAM83F, along with the novel targets CYP2R1, FIZ1, CDIP1, DAGLB, and ENTPD5. Two proteins (in red labels) were increased: GTF2H3 (FC = 1.67, adjusted p = 0.0022) and NFYA (FC = 2.27, adjusted p = 0.035). NFYA is necessary for hematopoietic stem cell proliferation . ( H ) Western blot of HUDEP-2 cells at stage 2 treated for 6 hours confirms degradation of IKZF1, shows no detectable degradation of BCL11A, and verifies the presence of ZNF410, which was not detected in the mass spectrometry (Supplementary Table S5). FC = fold change. AdjP = adjusted p-value.
    Lenalidomide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lenalidomide/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    lenalidomide - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    99
    TargetMol lenalidomide
    Summary of pomalidomide- and <t>lenalidomide-derivative</t> compound screen for HbF inducers in HUDEP-2 cells and unbiased global proteomic follow-up. For screening, cells were treated at stages 1 and 2 and collected at stage 3 (see ). ( A ) Pomalidomide (Poma) treatment (1 µM, 6 days) in HUDEP-2 cells induces a 4-fold increase of %HbF + cells as quantified by flow cytometry (p < 0.0001, two-sided t-test). ( B ) A total of 19 compounds induced HbF levels to at least 50% of the internal pomalidomide positive control, as quantified by flow cytometry. Compounds discussed in text are highlighted in color. Compounds 1088 (4-carbon linker), 1089 (5-carbon linker) and 1091 (7-carbon linker) share chemical structure similarity with 1090 , which contains a 6-carbon linker (Supplementary Table S4). ( C ) Direct targets of pomalidomide in HUDEP-2 cells (indicated by asterisks) include known targets IKZF1 and FAM83F and novel targets FBXO22, RASSF5, CDIP1, and KCTD15 (Supplementary Table S6). ( D ) Compound 1075 led to specific degradation of IKZF1 and ZFP91. ( E ) Compound 1090 led to degradation of a subset of major pomalidomide targets, with increased specificity for ZFP91 and CYP2R1. ( F ) Compound 1126 led to degradation of a subset of pomalidomide targets with increased specificity for CYP2R1 and ZPF91 and decreased specificity for IKZF1. ( G ) Compound 1235 , a derivative of lenalidomide, led to degradation of the known lenalidomide targets (indicated by asterisks) IKZF1, CSNK1A1, and FAM83F, along with the novel targets CYP2R1, FIZ1, CDIP1, DAGLB, and ENTPD5. Two proteins (in red labels) were increased: GTF2H3 (FC = 1.67, adjusted p = 0.0022) and NFYA (FC = 2.27, adjusted p = 0.035). NFYA is necessary for hematopoietic stem cell proliferation . ( H ) Western blot of HUDEP-2 cells at stage 2 treated for 6 hours confirms degradation of IKZF1, shows no detectable degradation of BCL11A, and verifies the presence of ZNF410, which was not detected in the mass spectrometry (Supplementary Table S5). FC = fold change. AdjP = adjusted p-value.
    Lenalidomide, supplied by TargetMol, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lenalidomide/product/TargetMol
    Average 99 stars, based on 1 article reviews
    lenalidomide - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    93
    MedChemExpress lenalidomidepropargyl c2 nh2 hydrochloride
    Summary of pomalidomide- and <t>lenalidomide-derivative</t> compound screen for HbF inducers in HUDEP-2 cells and unbiased global proteomic follow-up. For screening, cells were treated at stages 1 and 2 and collected at stage 3 (see ). ( A ) Pomalidomide (Poma) treatment (1 µM, 6 days) in HUDEP-2 cells induces a 4-fold increase of %HbF + cells as quantified by flow cytometry (p < 0.0001, two-sided t-test). ( B ) A total of 19 compounds induced HbF levels to at least 50% of the internal pomalidomide positive control, as quantified by flow cytometry. Compounds discussed in text are highlighted in color. Compounds 1088 (4-carbon linker), 1089 (5-carbon linker) and 1091 (7-carbon linker) share chemical structure similarity with 1090 , which contains a 6-carbon linker (Supplementary Table S4). ( C ) Direct targets of pomalidomide in HUDEP-2 cells (indicated by asterisks) include known targets IKZF1 and FAM83F and novel targets FBXO22, RASSF5, CDIP1, and KCTD15 (Supplementary Table S6). ( D ) Compound 1075 led to specific degradation of IKZF1 and ZFP91. ( E ) Compound 1090 led to degradation of a subset of major pomalidomide targets, with increased specificity for ZFP91 and CYP2R1. ( F ) Compound 1126 led to degradation of a subset of pomalidomide targets with increased specificity for CYP2R1 and ZPF91 and decreased specificity for IKZF1. ( G ) Compound 1235 , a derivative of lenalidomide, led to degradation of the known lenalidomide targets (indicated by asterisks) IKZF1, CSNK1A1, and FAM83F, along with the novel targets CYP2R1, FIZ1, CDIP1, DAGLB, and ENTPD5. Two proteins (in red labels) were increased: GTF2H3 (FC = 1.67, adjusted p = 0.0022) and NFYA (FC = 2.27, adjusted p = 0.035). NFYA is necessary for hematopoietic stem cell proliferation . ( H ) Western blot of HUDEP-2 cells at stage 2 treated for 6 hours confirms degradation of IKZF1, shows no detectable degradation of BCL11A, and verifies the presence of ZNF410, which was not detected in the mass spectrometry (Supplementary Table S5). FC = fold change. AdjP = adjusted p-value.
    Lenalidomidepropargyl C2 Nh2 Hydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lenalidomidepropargyl c2 nh2 hydrochloride/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    lenalidomidepropargyl c2 nh2 hydrochloride - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress lenalidomide propargyl c 2 nh 2 hydrochloride
    Summary of pomalidomide- and <t>lenalidomide-derivative</t> compound screen for HbF inducers in HUDEP-2 cells and unbiased global proteomic follow-up. For screening, cells were treated at stages 1 and 2 and collected at stage 3 (see ). ( A ) Pomalidomide (Poma) treatment (1 µM, 6 days) in HUDEP-2 cells induces a 4-fold increase of %HbF + cells as quantified by flow cytometry (p < 0.0001, two-sided t-test). ( B ) A total of 19 compounds induced HbF levels to at least 50% of the internal pomalidomide positive control, as quantified by flow cytometry. Compounds discussed in text are highlighted in color. Compounds 1088 (4-carbon linker), 1089 (5-carbon linker) and 1091 (7-carbon linker) share chemical structure similarity with 1090 , which contains a 6-carbon linker (Supplementary Table S4). ( C ) Direct targets of pomalidomide in HUDEP-2 cells (indicated by asterisks) include known targets IKZF1 and FAM83F and novel targets FBXO22, RASSF5, CDIP1, and KCTD15 (Supplementary Table S6). ( D ) Compound 1075 led to specific degradation of IKZF1 and ZFP91. ( E ) Compound 1090 led to degradation of a subset of major pomalidomide targets, with increased specificity for ZFP91 and CYP2R1. ( F ) Compound 1126 led to degradation of a subset of pomalidomide targets with increased specificity for CYP2R1 and ZPF91 and decreased specificity for IKZF1. ( G ) Compound 1235 , a derivative of lenalidomide, led to degradation of the known lenalidomide targets (indicated by asterisks) IKZF1, CSNK1A1, and FAM83F, along with the novel targets CYP2R1, FIZ1, CDIP1, DAGLB, and ENTPD5. Two proteins (in red labels) were increased: GTF2H3 (FC = 1.67, adjusted p = 0.0022) and NFYA (FC = 2.27, adjusted p = 0.035). NFYA is necessary for hematopoietic stem cell proliferation . ( H ) Western blot of HUDEP-2 cells at stage 2 treated for 6 hours confirms degradation of IKZF1, shows no detectable degradation of BCL11A, and verifies the presence of ZNF410, which was not detected in the mass spectrometry (Supplementary Table S5). FC = fold change. AdjP = adjusted p-value.
    Lenalidomide Propargyl C 2 Nh 2 Hydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lenalidomide propargyl c 2 nh 2 hydrochloride/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    lenalidomide propargyl c 2 nh 2 hydrochloride - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    A , B SerpinB2 was quantified in THP-1 macrophages after stimulation with IFN-γ in the presence or absence of Bay-118072, an NF-kB inhibitor, by qPCR ( A ) (n = 8/group) and confocal imaging ( B ) (n = 10/group). A , B each dot represents cells cultured in one well. C VAT from lean and obese mice were stained for the markers of fibroblasts, macrophages, and adipocytes along with IFN-γ. The frequencies of IFN-γ-expressing cells were assessed by confocal microscopy (n = 5/group) Scale bar=20 µm. D – J LysM +/+ Ifngr1 fl/fl and LysM cre/+ Ifngr1 fl/fl mice were fed with an HFD for four months. D VAT resident macrophages, SerpinB2-expressing macrophages, and caspase 3 + resident macrophages were measured by confocal microscopy (n = 12/group). E The frequencies of apoptotic (annexin V + PI − ) macrophages were measured by flow cytometry (n = 5 for WT and 4 for KO). F GTT and ITT were performed, and fasting blood glucose, serum insulin, lipid concentrations, and body weights were evaluated (n = 10/group, combined data of at least 2 independent experiments). G , H Immunoblot showing pAkt, total Akt, Glut4, adiponectin, and Ppar y expressions in muscle, visceral adipose. and liver (n = 6/group). I , J qPCR was carried out to measure the expression of the metabolic and inflammatory genes in VAT (n = 7/group). K , L The top four transcription factors predicted to bind to the SerpinB2 promoter ( K ), and ChIP validation of Ikaros binding to the SerpinB2 promoter ( L ) (n = 4/group, with two sets of primers) are shown. M Ikaros quantification by qPCR in BMDM cultured in the presence or absence of 250 milli units IFN-γ (n = 10 and 8 for with and without IFN-γ, respectively). L , M each dot represents cells cultured in one well. N SerpinB2 expression in BMDM treated with or without IFN-γ and lenalidomide (representative image of the 3 independent experiments). O Ifngr1 and Ifngr2 were quantified by RNA seq in the adipose macrophage subsets (n = 3/group, each dot represents one mouse.). P – R Evaluation of apoptosis in BMDM lacking SerpinB2 (P) (n = 6/group), THP-1 macrophages overexpressing SerpinB2 ( Q ) (n = 4/group), and VAT resident macrophages in obese SerpinB2 +/+ and SerpinB2 − / − mice ( R ) (n = 4 for WT and 6 for KO) by flow cytometry. * P < 0.05, ** P < 0.01, *** P < 0.001. The Mann Whitney test (two-tailed) was used to determine the significance between two groups. One-way ANOVA with Bonferoni’s post hoc correction test was performed to determine differences among data obtained from more than two groups (Fig. 4B).

    Journal: Nature Communications

    Article Title: Tissue-resident macrophage survival depends on mitochondrial function regulated by SerpinB2 in chronic inflammation

    doi: 10.1038/s41467-026-69196-4

    Figure Lengend Snippet: A , B SerpinB2 was quantified in THP-1 macrophages after stimulation with IFN-γ in the presence or absence of Bay-118072, an NF-kB inhibitor, by qPCR ( A ) (n = 8/group) and confocal imaging ( B ) (n = 10/group). A , B each dot represents cells cultured in one well. C VAT from lean and obese mice were stained for the markers of fibroblasts, macrophages, and adipocytes along with IFN-γ. The frequencies of IFN-γ-expressing cells were assessed by confocal microscopy (n = 5/group) Scale bar=20 µm. D – J LysM +/+ Ifngr1 fl/fl and LysM cre/+ Ifngr1 fl/fl mice were fed with an HFD for four months. D VAT resident macrophages, SerpinB2-expressing macrophages, and caspase 3 + resident macrophages were measured by confocal microscopy (n = 12/group). E The frequencies of apoptotic (annexin V + PI − ) macrophages were measured by flow cytometry (n = 5 for WT and 4 for KO). F GTT and ITT were performed, and fasting blood glucose, serum insulin, lipid concentrations, and body weights were evaluated (n = 10/group, combined data of at least 2 independent experiments). G , H Immunoblot showing pAkt, total Akt, Glut4, adiponectin, and Ppar y expressions in muscle, visceral adipose. and liver (n = 6/group). I , J qPCR was carried out to measure the expression of the metabolic and inflammatory genes in VAT (n = 7/group). K , L The top four transcription factors predicted to bind to the SerpinB2 promoter ( K ), and ChIP validation of Ikaros binding to the SerpinB2 promoter ( L ) (n = 4/group, with two sets of primers) are shown. M Ikaros quantification by qPCR in BMDM cultured in the presence or absence of 250 milli units IFN-γ (n = 10 and 8 for with and without IFN-γ, respectively). L , M each dot represents cells cultured in one well. N SerpinB2 expression in BMDM treated with or without IFN-γ and lenalidomide (representative image of the 3 independent experiments). O Ifngr1 and Ifngr2 were quantified by RNA seq in the adipose macrophage subsets (n = 3/group, each dot represents one mouse.). P – R Evaluation of apoptosis in BMDM lacking SerpinB2 (P) (n = 6/group), THP-1 macrophages overexpressing SerpinB2 ( Q ) (n = 4/group), and VAT resident macrophages in obese SerpinB2 +/+ and SerpinB2 − / − mice ( R ) (n = 4 for WT and 6 for KO) by flow cytometry. * P < 0.05, ** P < 0.01, *** P < 0.001. The Mann Whitney test (two-tailed) was used to determine the significance between two groups. One-way ANOVA with Bonferoni’s post hoc correction test was performed to determine differences among data obtained from more than two groups (Fig. 4B).

    Article Snippet: In a separate experiment, BMDMs were treated with or without Ikaros inhibitor lenalidomide (5 μM) (MedChemExpress, #HYA0003) for 2 hours followed by stimulation with 250 milliunits of IFN- γ for 24 hours.

    Techniques: Imaging, Cell Culture, Staining, Expressing, Confocal Microscopy, Flow Cytometry, Western Blot, Biomarker Discovery, Binding Assay, RNA Sequencing, MANN-WHITNEY, Two Tailed Test

    Summary of pomalidomide- and lenalidomide-derivative compound screen for HbF inducers in HUDEP-2 cells and unbiased global proteomic follow-up. For screening, cells were treated at stages 1 and 2 and collected at stage 3 (see ). ( A ) Pomalidomide (Poma) treatment (1 µM, 6 days) in HUDEP-2 cells induces a 4-fold increase of %HbF + cells as quantified by flow cytometry (p < 0.0001, two-sided t-test). ( B ) A total of 19 compounds induced HbF levels to at least 50% of the internal pomalidomide positive control, as quantified by flow cytometry. Compounds discussed in text are highlighted in color. Compounds 1088 (4-carbon linker), 1089 (5-carbon linker) and 1091 (7-carbon linker) share chemical structure similarity with 1090 , which contains a 6-carbon linker (Supplementary Table S4). ( C ) Direct targets of pomalidomide in HUDEP-2 cells (indicated by asterisks) include known targets IKZF1 and FAM83F and novel targets FBXO22, RASSF5, CDIP1, and KCTD15 (Supplementary Table S6). ( D ) Compound 1075 led to specific degradation of IKZF1 and ZFP91. ( E ) Compound 1090 led to degradation of a subset of major pomalidomide targets, with increased specificity for ZFP91 and CYP2R1. ( F ) Compound 1126 led to degradation of a subset of pomalidomide targets with increased specificity for CYP2R1 and ZPF91 and decreased specificity for IKZF1. ( G ) Compound 1235 , a derivative of lenalidomide, led to degradation of the known lenalidomide targets (indicated by asterisks) IKZF1, CSNK1A1, and FAM83F, along with the novel targets CYP2R1, FIZ1, CDIP1, DAGLB, and ENTPD5. Two proteins (in red labels) were increased: GTF2H3 (FC = 1.67, adjusted p = 0.0022) and NFYA (FC = 2.27, adjusted p = 0.035). NFYA is necessary for hematopoietic stem cell proliferation . ( H ) Western blot of HUDEP-2 cells at stage 2 treated for 6 hours confirms degradation of IKZF1, shows no detectable degradation of BCL11A, and verifies the presence of ZNF410, which was not detected in the mass spectrometry (Supplementary Table S5). FC = fold change. AdjP = adjusted p-value.

    Journal: bioRxiv

    Article Title: Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells

    doi: 10.64898/2026.02.06.704516

    Figure Lengend Snippet: Summary of pomalidomide- and lenalidomide-derivative compound screen for HbF inducers in HUDEP-2 cells and unbiased global proteomic follow-up. For screening, cells were treated at stages 1 and 2 and collected at stage 3 (see ). ( A ) Pomalidomide (Poma) treatment (1 µM, 6 days) in HUDEP-2 cells induces a 4-fold increase of %HbF + cells as quantified by flow cytometry (p < 0.0001, two-sided t-test). ( B ) A total of 19 compounds induced HbF levels to at least 50% of the internal pomalidomide positive control, as quantified by flow cytometry. Compounds discussed in text are highlighted in color. Compounds 1088 (4-carbon linker), 1089 (5-carbon linker) and 1091 (7-carbon linker) share chemical structure similarity with 1090 , which contains a 6-carbon linker (Supplementary Table S4). ( C ) Direct targets of pomalidomide in HUDEP-2 cells (indicated by asterisks) include known targets IKZF1 and FAM83F and novel targets FBXO22, RASSF5, CDIP1, and KCTD15 (Supplementary Table S6). ( D ) Compound 1075 led to specific degradation of IKZF1 and ZFP91. ( E ) Compound 1090 led to degradation of a subset of major pomalidomide targets, with increased specificity for ZFP91 and CYP2R1. ( F ) Compound 1126 led to degradation of a subset of pomalidomide targets with increased specificity for CYP2R1 and ZPF91 and decreased specificity for IKZF1. ( G ) Compound 1235 , a derivative of lenalidomide, led to degradation of the known lenalidomide targets (indicated by asterisks) IKZF1, CSNK1A1, and FAM83F, along with the novel targets CYP2R1, FIZ1, CDIP1, DAGLB, and ENTPD5. Two proteins (in red labels) were increased: GTF2H3 (FC = 1.67, adjusted p = 0.0022) and NFYA (FC = 2.27, adjusted p = 0.035). NFYA is necessary for hematopoietic stem cell proliferation . ( H ) Western blot of HUDEP-2 cells at stage 2 treated for 6 hours confirms degradation of IKZF1, shows no detectable degradation of BCL11A, and verifies the presence of ZNF410, which was not detected in the mass spectrometry (Supplementary Table S5). FC = fold change. AdjP = adjusted p-value.

    Article Snippet: Chemical compounds GSK3484862 (HY-135146), FTX6058 (HY-139400), pomalidomide (HY-10984) and lenalidomide (HY-A0003) were purchased from MedChemExpress.

    Techniques: Flow Cytometry, Positive Control, Western Blot, Mass Spectrometry

    Models of BCL11A regulation across three complementary layers. ( A ) The ZF0-mediated oligomerization assembles different BCL11A splice variants (depicted as different lengths), all of which contain ZF0, enabling BCL11A to form high-order polymers. ( B ) The EED inhibitor FTX6058 reduces BCL11A dosage mainly through LIN28B, which modulates BCL11A translation. ( C ) Sequence alignment of known pomalidomide degrons (IKZF1 and ZFP91) and dWIZ-2 target (WIZ), and the corresponding ZF units of ZNF410 and BCL11A. Zinc-coordinating residues are colored blue, and residues critical for the selectivity of pomalidomide- or lenalidomide-derived degraders are shown in red. ( D ) The pomalidomide-derived compound 1075 induces degradation of ZFP91 and IKZF1, reshaping the regulatory network contributing to HbF induction.

    Journal: bioRxiv

    Article Title: Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells

    doi: 10.64898/2026.02.06.704516

    Figure Lengend Snippet: Models of BCL11A regulation across three complementary layers. ( A ) The ZF0-mediated oligomerization assembles different BCL11A splice variants (depicted as different lengths), all of which contain ZF0, enabling BCL11A to form high-order polymers. ( B ) The EED inhibitor FTX6058 reduces BCL11A dosage mainly through LIN28B, which modulates BCL11A translation. ( C ) Sequence alignment of known pomalidomide degrons (IKZF1 and ZFP91) and dWIZ-2 target (WIZ), and the corresponding ZF units of ZNF410 and BCL11A. Zinc-coordinating residues are colored blue, and residues critical for the selectivity of pomalidomide- or lenalidomide-derived degraders are shown in red. ( D ) The pomalidomide-derived compound 1075 induces degradation of ZFP91 and IKZF1, reshaping the regulatory network contributing to HbF induction.

    Article Snippet: Chemical compounds GSK3484862 (HY-135146), FTX6058 (HY-139400), pomalidomide (HY-10984) and lenalidomide (HY-A0003) were purchased from MedChemExpress.

    Techniques: Sequencing, Derivative Assay